论文信息 - Switching between antitumour necrosis factor alpha biologic agents — is patient weight an important consideration?

Switching between antitumour necrosis factor alpha biologic agents — is patient weight an important consideration?

1 Su LD, Duncan LM. Lymphomaand leukemia-associated cutaneous atypical CD30+ T-cell reactions. J Cutan Pathol 2000; 27:249–54. 2 Magro CM, Crowson AN, Kovatich AJ, Burns F. Drug-induced reversible lymphoid dyscrasia: a clonal lymphomatoid dermatitis of memory and activated T cells. Hum Pathol 2003; 34:119–29. 3 Kempf W. CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators. J Cutan Pathol 2006; 33 (Suppl. 1):58–70.

A. Downs

[1] M. Lebwohl,et al. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. , 2008, Journal of the American Academy of Dermatology.

[2] J. Saurat,et al. Infliximab then Efalizumab, the ‘Hit and Run’ Approach Does Not Work , 2008, Dermatology.

[3] R. Kalb,et al. Infliximab in the treatment of psoriasis in patients previously treated with etanercept. , 2007, Journal of the American Academy of Dermatology.

[4] J. Sánchez-Carazo,et al. Treatment of psoriasis with adalimumab , 2006, Clinical and experimental dermatology.

[5] A. Kovatich,et al. Drug-induced reversible lymphoid dyscrasia: a clonal lymphomatoid dermatitis of memory and activated T cells. , 2003, Human pathology.